Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy

Author(s): Ana Vanessa Nascimento, Hassan Bousbaa, Domingos Ferreira, Bruno Sarmento

Journal Name: Current Drug Targets

Volume 16 , Issue 13 , 2015

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Non-small cell lung cancer (NSCLC) represents close to 90% of all lung cancers. When diagnosed, most cases are on an advanced and inoperable stage, with limited therapeutic options. Existing therapies have shown to be insufficient and novel strategies are urgently necessary. New advances in understanding the disease at cellular and molecular level however have helped researchers in devising novel strategies for therapy. These directed therapies limit cancer growth by targeting specific molecules related with tumor progression. Such strategies have shown to be more effective than chemotherapy and radiotherapy and can be complemented to existing therapeutic paradigm in augmenting beneficial outcome. Lung cancer could benefit from such innovative therapy. RNA interference (RNAi) is a sequence-specific gene silencing mechanism and, since its discovery widespread applications have pointed it as a powerful tool in cancer treatment. Several on-going clinical trials have been successfully demonstrating its potential as a novel therapeutic, including in the treatment of NSCLC. Here, we revise the recent findings concerning the therapeutic effects of molecular variations associated with NSCLC and where targeted therapies stand in its treatment, with special focus on RNAi-mediated gene silencing as a powerful strategy for NSCLC treatment.

Keywords: Angiogenesis, apoptosis, monoclonal antibody, non-small cell lung cancer, RNA interference, signal transduction, small molecules, targeted therapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [1448 - 1463]
Pages: 16
DOI: 10.2174/1389450115666140528151649
Price: $65

Article Metrics

PDF: 49